150 North Hill Drive, Suite 24
17 articles with Dance Biopharm
9/23/2019Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Dance Biopharm Presents Encouraging Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting
Dance Biopharm Holdings, Inc. presented Phase 2 Samba 04 clinical trial results for its inhaled preservative-free human insulin, Dance 501, for the treatment of type 2 diabetes.
Dance Biopharm to Present Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting
This trial, conducted in patients with type 2 diabetes, compared three doses each of Dance 501 inhaled insulin and subcutaneous insulin lispro
Financial Matters Expert to Serve as Chair of Audit Committee
Proceeds to provide support for development of Dance’s novel inhaled biologic products
Dance Biopharm Strengthens Leadership Team to Advance Late-Stage Diabetes Development Program and Transition Pipeline Candidates into Clinical Trials
Dr. Melissa Rhodes to the position of Chief Development Officer and Mr. Michael Kaseta to the role of Chief Financial Officer.
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
Dance Biopharm Holdings Inc. is pleased to announce that Anne Whitaker has been appointed as a Director and Chief Executive Officer.
Dance Biopharm and Phillips-Medisize Enter Into Joint Development Agreement for Advanced Inhaled Insulin Delivery
Dance has awarded Phillips-Medisize the development work associated with future enhancements to Dance's devices as well as the commercial manufacturing of Dance's inhaled insulin device when it comes to market.
Dance Biopharm's China Licensee, Harmony Biopharm, Enters Into New Joint Venture With Tonghua Dongbao Pharmaceutical Co., Ltd, A Leading China Insulin Producer
Dance Biopharma Announces Joint Venture With Harmony Asset for the Development of Inhaled Insulin in Multiple Countries in Asia
Dance Biopharma Announces Encouraging Clinical Data for Adagio™-- Inhalable Insulin Product Candidate for Diabetes